NCT06649435Completed
Seerlinq: Non-invasive LVFP Monitoring in HF
Seerlinq: a Non-invasive System for Remote Monitoring of Left Ventricular Filling Pressure in Heart Failure Patients
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
Left ventricular filling pressure (LVFP) monitoring has been associated with improved quality of life, survival and reduced hospitalization rates. However, current LVFP monitoring methods are invasive, costly, and require long-term antithrombotic therapy. The purpose of this study is to validate Seerlinq HeartCore, a novel CE-certified, non-invasive system that enables remote LVFP monitoring using photoplethysmography (PPG) and machine learning-based signal analysis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 131 (actual)
- First submitted
- 15 Oct 2024
- Start date
- 1 Mar 2023
- Primary completion date
- 1 Dec 2023
- Lead sponsor
- Seerlinq s. r. o.
- Diseases
- Heart failure
- NCT number
- NCT06649435
What you commit to
- Study type: Observational
- Participants enrolled: 131
- From 1 Mar 2023 to the primary completion date, 1 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Advanced renal failure (glomerular filtration rate \<25 ml/min or need for renal replacement therapy),
- Active malignancy requiring chemotherapy or radiotherapy
- Complex congenital heart disease
- Pulmonary hypertension classified as WHO group 1 or groups 3-5.
- Other possible unforeseen medical conditions that the investigator deems unsafe for study participation
Other
- Pregnancy or female participant lactating
- Ventricular assist device support
Who the study is looking for
- Males and females aged ≥ 18 years
- Able to understand, and willing to provide written ICF
- Stated willingness to comply with all study procedures
- Confirmed diagnosis of heart failure according to the 2021 ESC guidelines
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seerlinq s.r.o. Coordinator of this site? Confirm its status | Bratislava | Slovakia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.